Romero sues supplement firms
This article was originally published in The Tan Sheet
Executive Summary
Phillies reliever J.C. Romero sues supplement makers Ergopharm and Proviant Technologies, allegedly the firms failed to list all ingredients on the label of 6-OXO Extreme, a testosterone boosting supplement. In the suit filed April 27 in the Superior Court in Camden, N.J., Romero alleges the supplement caused him to test positive for substances banned by Major League Baseball, resulting in his suspension during the 2008 World Series and for the first 50 games of this season. He seeks compensatory and punitive damages. Proviant Technologies disputes the allegations and told media 6-OXO Extreme warns on the label that using the product may be banned by some sports leagues or government associations. Earlier this year, supplement maker AdvoCare accused a professional swimmer of defamation after she and her coach suggested to media that its products were tainted with a prohibitied performance-enhancing substance. The athlete has filed a liability and negligent claim against Carrollton, Texas.-based AdvoCare (1"The Tan Sheet" Feb. 23, 2009, p. 6)
You may also be interested in...
AdvoCare’s Suit Aims At Athletes Falsely Blaming Supplements For Failed Tests
A high-stakes legal battle about allegedly contaminated dietary supplements could make athletes who test positive for banned substances think twice before blaming dietary supplements
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.